Ranitidine Form 1 ANDAs should not have to challenge Form 2, Mylan tells FDA in petition.
RANITIDINE FORM 1 ANDAs SHOULD NOT HAVE TO CHALLENGE FORM 2, Mylan contends in a citizen petition submitted to FDA Jan. 13. The Morgantown, W.V.-based generic company is asking FDA to "distinguish between ranitidine HCl Form 1, and ranitidine HCl Form 2 for the purposes of patent certification." Applications for generic versions of ranitidine Form 1 that contain a paragraph III certification regarding the Form 1 ('658) ranitidine patent, which expires in July, should be approvable, Mylan says.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth